Group items tagged

The purpose of this funding opportunity announcement (FOA) is to advance translational research for rare musculoskeletal, rheumatic or skin diseases by supporting preclinical projects conducted by small business concerns (SBCs) to develop biomarkers and/or therapies. The 2010 Institute of Medicine Report "Rare Diseases and Orphan Products: Accelerating Research and Development" (https://www.nap.edu/read/12953/chapter/1) called for active involvement and collaboration by the public and private sectors, and emphasized the role of NIH in integrating various stake holders into a comprehensive strategy for supporting all phases of rare diseases research. NIAMS supports research on rare diseases and orphan drugs through various grant mechanisms including research project grants, center awards and training/career development awards. SBCs play an important role in disease research by developing innovative technologies and increasing the commercial application of federally supported research results. However, it can be more challenging for SBCs to achieve profitability in rare diseases research and development due to inherent scientific risks and market limitations caused by the small number of individuals affected by each disease. With this FOA, NIAMS intends to support and enhance research and development conducted by SBCs that may lead to important biomarkers and/or treatments for rare musculoskeletal, rheumatic or skin diseases.

This Small Business Technology Transfer (STTR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R&D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics. The NIDCD supports research on the normal mechanisms of, as well as on diseases and disorders of hearing, balance, smell, taste, voice, speech and language. The Institute also supports research related to disease prevention and health promotion. The NIDCD addresses special biomedical and behavioral problems associated with people who have communication impairments or disorders. The NIDCD also supports efforts to create and refine devices, as well as develop cellular-based applications that may replace or substitute for lost and impaired sensory and communication functions.

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the Administration for Children and Families (ACF) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, FDA or ACF awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics. The NIDCR conducts and fosters research on the etiology, pathogenesis, prevention, diagnosis, and treatment of oral, craniofacial and dental diseases and conditions.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) Fast Track grant applications that propose to test and/or validate novel, state-of-the-art candidate biomarker platforms for predicting the onset and progression of inflammatory diseases of interest to the NIAMS and for determining the pharmacodynamics, safety and/or efficacy of therapeutic agents targeting those diseases.

The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) research grant applications to develop next-generation tools that distinguish heterogeneous states among cells and have commercial potential. Applications should define the current state of technology as a benchmark against which the new tool(s) will be measured.  Applications should also propose proof-of-concept testing of the tool(s) in a complex biological tissue or living organism. The new tools should provide substantially increased sensitivity, selectivity, spatiotemporal resolution, scalability or non-destructive analysis of multiple global or functional measures of single cells. These novel technologies will aid in obtaining a fine-grained, integrative and dynamic view of heterogeneous cellular states/classes and will provide innovative platforms to transform research into the cellular basis of diseases. 

This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose to develop or improve technologies for obtaining, characterizing and testing animal and human stem cells and their derivatives as models for stem cell-based regenerative medicine using animal models. The program is intended to support projects devoted to the creation of informative animal models for regenerative medicine, which will facilitate testing the safety and therapeutic potential of animal and human stem cells and their derivatives for pre-clinical evaluation. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cells and their derivatives, including production, characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications. The ultimate objective of these efforts should be to provide commercial products and technologies that can help develop future clinical therapies.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop or improve technologies for obtaining, characterizing and testing animal and human stem cells and their derivatives as models for stem cell-based regenerative medicine using animal models. The program is intended to support projects devoted to the creation of informative animal models for regenerative medicine, which will facilitate testing the safety and therapeutic potential of animal and human stem cells and their derivatives for pre-clinical evaluation. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cells and their derivatives, including production, characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications. The ultimate objective of these efforts should be to provide commercial products and technologies that can help develop future clinical therapies.

This Funding Opportunity Announcement (FOA) reissued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the Administration for Children and Families (ACF) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, FDA or ACF awarding components identified in this FOA are encourag

The purpose of this initiative is to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease. 

This funding opportunity announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) to develop and validate next-generation single cell analysis technologies and tools. The purpose is to foster the commercialization of innovative single cell analysis technologies for their broad use in biomedical research. The novel single-cell analysis technologies will aid in obtaining a fine-grained and dynamic view of heterogeneous cellular states and intercellular interactions, thereby providing new mechanistic insight into biological processes in health and disease. Applications should define the current state of technologies and tools as a benchmark against which the new approach(es) will be measured. The new approach(es) should provide substantially improved performance in sensitivity, selectivity, spatiotemporal resolution, scalability, multiplexing capability, or non-destructive analysis of molecular or functional measures of single cells.